|
|
Vaccine Detail
|
GM2/GD2/GD3 Lactone-KLH Conjugate Trivalent Vaccine |
| Vaccine Information |
- Vaccine Name: GM2/GD2/GD3 Lactone-KLH Conjugate Trivalent Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007549
- Type: Conjugate vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- GM2A
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- GRDX
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A trivalent cancer vaccine containing the ganglioside lactones GM2, GD2 and GD3 conjugated with the immunostimulant keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with GM2 lactone/GD2 lactone/GD3 lactone-KLH conjugate trivalent vaccine may elicit antibodies against tumor cells expressing any of these epitopes, resulting in an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing these gangliosides. GM2, GD2 and GD3 are tumor associated antigens (TAAs) that are overexpressed in a variety of tumor cell membranes. (NCIT_C91377).
|
| Host Response |
|
|
| References |
NCIT_C91377: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C91377]
|
|
